All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 7 read as filed from the record and 2 are SI estimates, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
1 warning event since 2017; the latest 2017-03-31.
From the record
Madrigal Pharmaceuticals, Inc.'s filings since 2017 show 1 warning event: a warning not to rely on past financial statements (8-K item 4.02, the latest 2017-03-31) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
4 filed years; profitable in 0 of 4.
From the record
Madrigal Pharmaceuticals, Inc.'s 4 filed years say what it did: it rose in 1 of 1 years; it never fell from a peak; net income was positive in 0 of 4 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 6.6/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Madrigal Pharmaceuticals, Inc.'s shareholder treatment is put at 6.6 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 34% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -48%: lost 48¢ per shareholder dollar. Leverage 52%: owes 52¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Madrigal Pharmaceuticals, Inc. lost about 48 cents for every dollar of shareholders' money. Leverage: it owed about 52 cents per dollar of assets, and net share issuance: its share count grew 5.5% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
top 24% of 315 in its family; net margin -30.1%.
From the record
Madrigal Pharmaceuticals, Inc.'s standing among 315 graded names in its industry family: revenue of $958 million in fiscal 2025 ranks in the top 12% by size; a net margin of -30.1% ranks in the top 36% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
bottom 31% of 315 in its family for leadership; chief executive since 2023.
From the record
Madrigal Pharmaceuticals, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Sibold, William John (President and CEO, as filed), filing under that title since 2023-09-13, 3.2 years (bottom 34% of its family); the 16 officers and directors filing in the last fifteen months have been on the record a median of 3.1 years (bottom 16%); 8 officer or director changes were reported on Form 8-K since 2023-11-13, against the 16 people in charge now (bottom 45%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
bottom 37% of 273 in its family for room to expand.
From the record
Madrigal Pharmaceuticals, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $199 million against debt of $340 million leaves -11.2% of its assets as net cash, bottom 9% of its family; cash from operations less capital spending is -19.8% of revenue (top 38%); research spending of 40.5% of revenue (bottom 39%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
top 18% of 306 in its family for growth drivers.
From the record
Madrigal Pharmaceuticals, Inc.'s growth drivers, from the filed years to fiscal 2025: the newest year grew 432.7% (top 7%); research spending grew 16.5% a year (top 27%); capital spending grew 29.1% a year (top 20%) (its annual reports). Madrigal Pharmaceuticals, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
SI estimate 5.5/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Madrigal Pharmaceuticals, Inc.'s expectations vs reality is put at 5.5 of 10 with a confidence of 35 of 100, because read from one part only, net income against the prior three years' average, which ranks in the top 44% of 284 in its family; the record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change. A filing that carries the missing parts replaces this estimate with the filed reading.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made